FIGO 2023 endometrial cancer staging: too much, too soon?

W Glenn McCluggage,Tjalling Bosse,C Blake Gilks,Brooke E Howitt,Jessica N McAlpine,Marisa R Nucci,Joseph T Rabban,Naveena Singh,Karen L Talia,Carlos Parra-Herran
DOI: https://doi.org/10.1136/ijgc-2023-004981
2023-11-07
International Journal of Gynecologic Cancer
Abstract:An updated International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial carcinoma was introduced in June 2023. The new system represents a significant departure from traditional endometrial and other gynecological carcinoma staging systems which are agnostic of parameters such as tumor type, tumor grade, lymphovascular space invasion, and molecular alterations. The updated system, which incorporates all of these ‘non-anatomical‘ parameters, is an attempt to make staging more personalized and relevant to patient prognostication and management, and to align with the European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology (ESGO/ESTRO/ESP) risk stratification. Herein, we present a critical review of the new staging system and discuss its advantages and disadvantages. The authors propose that the new FIGO staging system should be first appraised at a multi-institutional and global level with the input of all relevant societies (gynecology, pathology, gynecologic oncology, medical oncology, radiation oncology) to understand the impact, scope, and supporting evidence of the proposed changes. Such a process is fundamental to produce a robust system that pathologists and treating clinicians can adopt.
What problem does this paper attempt to address?